Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 18/20 | 0.63 |
| ▸ | PPARD | Q03181 | 12/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | PPARG | P37231 | 3/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL814790 | 0.89 | PPARA (0.67) | PPARAPPARDKCNH2PPARGABCG2 | |
| SCHEMBL13764684 | 0.89 | PPARA (0.51) | PPARAPPARDKCNH2PPARGABCG2 | |
| SCHEMBL814527 | 0.84 | PPARA (0.67) | PPARAPPARDKCNH2PPARG | |
| SCHEMBL3970580 | 0.84 | ABCG2 (0.50) | ABCG2ABCB1 | |
| SCHEMBL3970576 | 0.84 | ABCG2 (0.50) | ABCG2ABCB1 | |
| SCHEMBL13764724 | 0.82 | PPARA (0.58) | PPARAPPARDKCNH2PPARG | |
| SCHEMBL22279050 | 0.82 | PPARA (0.84) | PPARAPPARDKCNH2PPARG | |
| SCHEMBL13764698 | 0.81 | PPARA (0.67) | PPARAPPARDKCNH2PPARG | |
| SCHEMBL12464057 | 0.80 | PPARA (0.71) | PPARAPPARDKCNH2PPARG | |
| SCHEMBL11893126 | 0.79 | PPARA (0.65) | PPARAPPARDKCNH2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566737-B2 | Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2009-07-28 | — | — | US | disclosed |
| US-7566737-B2 | Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2009-07-28 | — | — | US | disclosed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | disclosed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | PSEN1, BACE1, PSEN2 | PPARA 69/4885PPARD 39/4885KCNH2 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.